Novel human single-domain antibodies exert potent anti-tumor activity by targeting EGF-like repeat epitope of EpCAM
This study provides compelling evidence that targeting EpCAM with sdAbs is a promising approach for cancer treatment. The identified anti-EpCAM sdAbs exhibit substantial anti-tumor activity both <i>in vitro</i> and <i>in vivo</i>, suggesting they are strong candidates for future therapeutic applications in cancer therapy.
Authors
- Zeyu Lin (ORCID: https://orcid.org/0000-0002-5401-5959)
- Xiaofeng Zhou (ORCID: https://orcid.org/0000-0001-9915-8163)
- Lin Dai (ORCID: https://orcid.org/0000-0002-2333-675X)
- Hong Pan (ORCID: https://orcid.org/0009-0005-7812-3347)
- Henry Wei (ORCID: https://orcid.org/0000-0002-5887-8348)
- Weixiong Zhang (ORCID: https://orcid.org/0000-0002-4998-9791)
- Tao Chen (ORCID: https://orcid.org/0000-0002-8433-2509)
- Qi Qi (ORCID: https://orcid.org/0000-0002-7974-9609)
- Zhifang Liu (ORCID: https://orcid.org/0000-0003-3270-2114)
Institutions
- Jinan University (CN)
- Shandong Provincial Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.3389/fphar.2025.1530268
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jinan University
- Basic and Applied Basic Research Foundation of Guangdong Province